Diabetes, Metabolic Syndrome and Obesity (Dec 2020)
Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial
Abstract
Hiroki Teragawa,1 Takeshi Morimoto,2 Yuichi Fujii,1 Tomohiro Ueda,1 Mio Sakuma,2 Michio Shimabukuro,3 Osamu Arasaki,4 Koichi Node,5 Takashi Nomiyama,6 Shinichiro Ueda7 1Department of Cardiovascular Medicine, JR Hiroshima Hospital, Hiroshima, Japan; 2Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan; 3Department of Diabetes, Endocrinology and Metabolism, Fukushima Medical University, Fukushima, Japan; 4Department of Cardiology, Tomishiro Central Hospital, Tomigusuku, Okinawa, Japan; 5Department of Cardiovascular Medicine, Saga University, Saga, Japan; 6Department of Endocrinology and Diabetes Mellitus, Fukuoka University, Fukuoka, Japan; 7Department of Clinical Pharmacology and Therapeutics, University of the Ryukyus, Nishihara, Okinawa, JapanCorrespondence: Hiroki TeragawaDepartment of Cardiovascular Medicine, JR Hiroshima Hospital, 3-1-36 Futabanosato, Higashi-ku, Hiroshima 732-0052, JapanTel +81-82-262-1171Fax +81-82-262-1499Email [email protected]: Experimental evidence has suggested that dipeptidyl peptidase-4 (DPP-4) inhibitors have an anti-inflammatory effect as well as a glucose-lowering effect, but this has yet to be confirmed in diabetic patients. Therefore, we examined the anti-inflammatory effects of two kinds of DPP-4 inhibitors in patients who participated in the randomized evaluation of anagliptin (ANA) vs sitagliptin (SITA) on low-density lipoprotein cholesterol in diabetes (REASON) Trial, which compared low-density lipoprotein-cholesterol lowering effects between (ANA) and SITA in patients with type 2 diabetes, dyslipidemia, and atherosclerotic vascular lesions.Patients and Methods: The studied patients consisted of 177 patients who received ANA 200 mg per day and 176 patients who received SITA 50 mg per day for 52 weeks. We measured high-sensitivity C-reactive protein (hs-CRP), white blood cells (WBC), and interleukin-6 (IL-6) before and after treatment for 52 weeks, and the changes in inflammatory markers were measured as the differences between baseline and 52 weeks. Furthermore, we checked the relationship between the change in hs-CRP and several clinical factors such as the baseline hs-CRP level, use of a moderate-intensity statin, presence of coronary artery disease (CAD) and taking a previous DDP-4 inhibitor.Results: The levels of the inflammatory markers hs-CRP, WBC, and IL-6 were determined to have not significantly changed from baseline to the final follow-up in each arm; furthermore, the changes in these markers were not significantly different between the two groups. The change in hs-CRP level was not affected by the baseline hs-CRP level, use of a moderate-intensity statin, presence of coronary artery disease, and absence of prior DPP-4 inhibitor use.Conclusion: In this sub-analysis from the REASON Trial, taking a DPP-4 inhibitor, either ANA or SITA, for 52 weeks did not affect the levels of inflammatory markers.Keywords: C-reactive protein, dipeptidyl peptidase-4, DPP-4 inhibitor, inflammation, interleukin-6, white blood cell
